Bristol-Myers Squibb submits new drug application to FDA for a fixed-dose combination of atazanavir sulfate with cobicistat for HIV-1
Bristol-Myers Squibb Company announced the submission of a new drug…
14 April 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced the submission of a new drug application to the U.S. Food and Drug Administration for a fixed-dose combination of atazanavir sulfate...